Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03471351 |
| Title | Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | Rhizen Pharmaceuticals SA |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| University of Chicago | Chicago | Illinois | 60637 | United States | Details | |
| Rhizen Pharmaceuticals investigational trial site; Karmanos Cancer Institute, | Detroit | Michigan | 48201 | United States | Details | |
| University of Washington | Seattle | Washington | 98109 | United States | Details |